To learn more about the research projects and team visit: VKPrasadLab
2023
409. Olivier T, Haslam A, Prasad V. Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival? Translational Oncology. 2023.
408. Olivier T, Tsantoulis P, Prasad V. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. European Urology. 2023.
407. Powell K, Olivier T, Prasad V. A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer. Trials. 2023
406. Haslam A, Olivier T, Prasad V. Design, power, and alpha levels in randomized phase II oncology trials. ESMO Open. 2023
405. Haslam A, Olivier T, Tuia J, Prasad V. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer. 2023
404. Powell K, Prasad V. Interpreting the results from the first randomised controlled trial of colonoscopy: does it save lives? BMJ Evidence Based Medicine. 2023
403. Buck E, Haslam A, Tuia J, Prasad V. Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals. JAMA Network Open. 2023
402. Haslam A, Olivier T, Tuia J, Prasad V. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. European Journal of Cancer. 2023.
401. Haslam A, Olivier T, Powell K, Tuia J, Prasad V. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. International Journal of Cancer. 2023.
2022
400. Knudsen B, Prasad V. COVID-19 vaccine induced myocarditis in young males: A systematic review. European Journal of Clinical Investigation. 2022.
399. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah A-O, Chakraborty R, Prasad V, Mohyuddin GR. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood Cancer Journal. 2022.
398. Powell K, Kakkilaya A, Haslam A, Prasad V. Financial conflicts of interest of OncoAlert: An informal oncology professional network. Journal of Cancer Policy. 2022.
397. Olivier T, Prasad V. Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC Medicine. 2022.
396. Powell K, Prasad V. Common misconceptions of randomized controlled trials in oncology. European Journal of Clinical Investigation. 2022.
395. Bhatt A, Powell K, Prasad V. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many? Translational Oncology. 2022.
394. Haslam A, Olivier T, Tuia J, Prasad V. Umbrella review of basket and umbrella trials in oncology European Journal of Cancer. 2022.
393. Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020. JAMA Internal Medicine. 2022.
392. Kim MS, Prasad V. Pembrolizumab for all. Journal of Cancer Research And Clinical Oncology. 2022.
391. Haslam A, Prasad V. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. The New England Journal of Medicine. 2022.
390. Prasad V, Ioannidis JPA. Constructive and obsessive criticism in science. European Journal of Clinical Investigation. 2022.
389. Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022.
388. Tuia JE, Olivier T, Prasad VK. Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care. American Journal of Clinical Oncology: Cancer Clinical Trials. 2022.
387. Jenei K, Lythgoe MP, Prasad V. General payments from Biogen to U.S. physicians between 2015 and 2020. Journal of The American Geriatrics Society. 2022.
386. Olivier T, Prasad V. Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? Translational Oncology. 2022.
385. Iness AN, Abaricia JO, Sawadogo W, Iness CM, Duesberg M, Cyrus J, Prasad V. The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review. The American Journal of Medicine. 2022.
384. Prasad V, Olivier T, Chen EY, Haslam A. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis. Journal of Cancer Policy. 2022.
383. Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005-2022. Journal of Cancer Policy. 2022.
382. Powell K, Burns MC, Prasad V. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. European Urology. 2022.
381. Olivier T, Powell K, Prasad V. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. European Urology. 2022.
380. Mohyuddin GR, Mehra N, Ryll B, Prasad V. Control participants of randomised trials: an often forgotten, vulnerable population. The Lancet. Haematology. 2022.
379. Jenei K, Lythgoe MP, Prasad V. CostPlus and implications for generic imatinib The Lancet Regional Health - Americas. 2022.
378. Olivier T, Haslam A, Prasad V. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. European Journal of Cancer. 2022.
377. Lythgoe MP, Prasad V. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. British Journal of Cancer. 2022.
376. Benjamin DJ, Haslam A, Gill J, Prasad V. Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer Medicine. 2022.
375. Haslam A, Prasad V. Characteristics of Facebook's third-party medical fact checkers. Digital Health. 2022.
374. Benjamin DJ, Prasad V. PI3K inhibitors in haematological malignancies. The Lancet. Oncology. 2022.
373. Powell K, Prasad V. Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF. BMJ Evidence-Based Medicine. 2022.
372. Olivier T, Gill J, Prasad V. Corrigendum to 'Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized' AmJMed 2021;135(4):413-415. The American Journal of Medicine. 2022.
371. Powell K, Prasad V. Multiplicity: When many analytic plans are applied or many redundant studies are run, false-positive results are ensured. European Journal of Clinical Investigation. 2022.
370. Van Oekelen O, Birrer N, Wesson W, Galate V, Goodman A, Abdallah A-O, Chakraborty R, Prasad V, Mohyuddin GR. P-053: A systematic review of measurable residual disease (MRD) assessment characteristics in myeloma trials from 2015-2020 Clinical Lymphoma Myeloma And Leukemia. 2022.
369. Etekal T, Koehn K, Sborov D, Mcclune B, Prasad V, Haslam A, Berger K, Booth C, Hadidi SA, Abdallah A-O, Goodman A, Mohyuddin GR. P-135: Time to event surrogate endpoints in multiple myeloma randomized trials from 2005-2019: a systematic review and surrogacy analysis Clinical Lymphoma Myeloma And Leukemia. 2022.
368. Olivier T, Prasad V. Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines. Translational Oncology. 2022.
367. Olivier T, Prasad V. FDA precedents in drug approvals: Contradiction in promoting more treatment options. European Journal of Cancer. 2022.
366. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians? JCO Oncology Practice. 2022.
365. Haslam A, Gill J, Prasad V. The frequency of assessment of progression in randomized oncology clinical trials. Cancer Reports. 2022.
364. Goodman AM, Mohyuddin GR, Prasad V. Ivosidenib and Azacitidine in IDH1-Mutated AML. The New England Journal of Medicine. 2022.
363. Prasad V, Olivier T, Chen EY, Haslam A. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: a cross sectional analysis . 2022.
362. Olivier T, Prasad V, Marini BL. Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. Blood Advances. 2022.
361. Smith CEP, Haslam A, Prasad V. Receipt of subsequent immune checkpoint inhibitors at progression among patients with solid tumors enrolled in clinical trials of adjuvant immune checkpoint inhibitors . 2022.
360. Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B. An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. Digestive Diseases And Sciences. 2022.
359. Kwong F, Lerner K, Tao DL, Patel S, Prasad V. ASCO oral presenters five years later: Leaks in the pipeline? Journal of Clinical Oncology. 2022.
358. Akman EG, Powell K, Haslam A, Prasad V. Characteristics of oncology podcasts: Attitudes, speakers, conflicts. Journal of Cancer Policy. 2022.
357. Mousavi I, Olivier T, Prasad V. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. JAMA Network Open. 2022.
356. Haslam A, Olivier T, Thawani R, Prasad V. Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm? Esmo Open. 2022.
355. Kim MS, Xu A, Haslam A, Prasad V. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. International Journal of Cancer. 2022.
354. Olivier T, Prasad V. Tebentafusp in first-line melanoma trials: An outperforming outlier. Translational Oncology. 2022.
353. Wayant C, Mohyuddin GR, Prasad V. The accelerated approval pathway in oncology: Balancing the benefits and potential harms. Journal of Cancer Policy. 2022.
352. Kim MS, Prasad V. When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence-Based Medicine. 2022.
351. Olivier T, Prasad V. Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. Journal of Clinical Oncology : Official Journal of The American Society of Clinical Oncology. 2022.
350. Ahmed N, Vengalasetti Y, Haslam A, Prasad V. Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials. JAMA Network Open. 2022.
349. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European Journal of Cancer. 2022.
348. Powell K, Prasad V. Where are randomized trials necessary: Are smoking and parachutes good counterexamples? European Journal of Clinical Investigation. 2022.
347. Haslam A, Powell K, Prasad V. How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature. Inquiry: The Journal of Health Care Organization, Provision, And Financing. 2022.
346. Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V. Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident. European Journal of Emergency Medicine : Official Journal of The European Society For Emergency Medicine. 2022.
345. Olivier T, Gill J, Prasad V. Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized. The American Journal of Medicine. 2022.
344. Gholami R, Khan R, Ramkissoon A, Alabdulqader A, Gimpaya N, Bansal R, Scaffidi MA, Prasad V, Detsky AS, Baker JP, Grover SC. Recommendation Reversals in Gastroenterology Clinical Practice Guidelines. Journal of The Canadian Association of Gastroenterology. 2022.
343. Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Translational Oncology. 2022.
342. Xu A, Prasad V. The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. Journal of Comparative Effectiveness Research. 2022.
341. Jenei K, Prasad V, Lythgoe MP. High US drug prices have global implications. BMJ. 2022.
340. Prasad V, Haslam A, Tuia J. A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. Journal of Cancer Policy. 2022.
339. Powell K, Kim MS, Haslam A, Prasad V. Artificial intelligence and magnetic resonance imaging may not make cancer screening better. Journal of Cancer Policy. 2022.
338. Benjamin DJ, Xu A, Lythgoe MP, Prasad V. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Network Open. 2022.
337. Greenstreet E, Powell K, Haslam A, Prasad V. Charateristics of Oncology Podcasts: Attitudes, Speakers, Conflicts. Journal of Cancer Policy 2022.
336. Benjamin D, Xu A, Lythgow M, Prasad V. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. Jama Network Open. 2022
335. Kim M, Xu A, Haslam A, Prasad V. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. International Journal of Cancer. 2022.
334. Xu A, Prasad V. The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. Future Medicine 2022
333. Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Translational Oncology 2022
332. Maniar A, Haslam A, Prasad V. Evaluating management of progressive disease for control arm patients in trials of first like PD-1 and PDL-1 inhibitor based treatment for metastatic solid tumors. EJC. 2022
331. Lythgow M, Prasad V. The Last Word On FDA draft guidance for cancer clinical trial eligibility for patients with incurable cancer. EJC
330. Sharp J, Prasad V. An estimate of the rate of deviation from NCCN guideline recommendations from CNS imaging in trials forming the basis of approval in NSCLC. BMC Cancer. 2022.
329. Powell K, Prasad V. Where are randomized trials necessary: Are smoking and parachutes good counterexamples? European Journal of Clinical Investigation. 2021
328. Powell K, Kim MS, Haslam A, Prasad V. Artificial intelligence and magnetic resonance imaging may not make cancer screening better. Journal of Cancer Policy. 2021
327. Powell K, Prasad V. Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF. BMJ Evid Based Med. 2021
326. Powell K, Prasad V. Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer. Transl Oncol. 2021
325. Prasad V, Haslam A, Tuia J. A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. Journal of Cancer Policy. 2022
324. Lythgoe M, Jenei K, Prasad V. Regulatory decisions diverge over aducanumab for Alzheimer’s disease. the BMJ. 2022.
323. Kim M, Xu A, Haslam A, Prasad V. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors between 2014-2020. Accepted
322. Olivier T, Haslam A, Prasad V. Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Netw Open. 2022;5(1):e2144770. doi:10.1001/jamanetworkopen.2021.44770
2021
321. Haslam A, Powell K, Prasad V. How often do medical specialties question the practices that they perform? An empirical, cross-sectional analysis of the published literature. Accepted
320. Haslam A, Kim MS, Prasad V. Overall survival for oncology drugs approved for genomic indications. European Journal of Cancer. 2021.
319. Powell K, Haslam A, Prasad V. An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence-Based? [published online ahead of print, 2021 Oct 19]. Am J Med. 2021;S0002-9343(21)00638-0. doi:10.1016/j.amjmed.2021.09.003
318. Olivier T, Prasad V. Elacestrant in metastatic breast cancer: is the “standard of care” meeting standard requirements ? Accepted
317. Fundytus A, Prasad V, Booth CM. Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing [published online ahead of print, 2021 Aug 26]. JAMA Oncol. 2021;10.1001/jamaoncol.2021.3600. doi:10.1001/jamaoncol.2021.3600
316. Jenei K. Raymakers A, Meyers DE, Prasad V. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015–2020
315. Kulkarni PA, Prasad V. Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Frontiers in Medicine.
314. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study.
313. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. British Journal of Haematology.
312. Liu I, Prasad V, Darrow JJ. Evidence for Community Cloth Face Masking to Limit the Spread of SARS‐CoV‑2: A Critical Review. Cato Institute Working Paper.
311. Olivier T, Prasad V. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Translational Oncology. 2021
310. Olivier T, Haslam A, Prasad V. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Netw Open. 2021;4(12):e2138793.
309. Lythgoe M, Olivier T, Prasad V. The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. European Journal of Cancer.
308. Haslam A, Lythgoe M, Greenstreet E, Prasad V. Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. Jama Network Open
307. Olivier T, Gill J, Prasad V. Multi-cancer screening tests: communicating about risks should be prioritized. American Journal of Medicine.
306. Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B. An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals [published online ahead of print, 2021 Aug 31]. Dig Dis Sci. 2021;10.1007/s10620-021-07199-5. doi:10.1007/s10620-021-07199-5
305. Meyers D, Chisamore T, McInnes M, Gyawali B, Prasad V, Booth C. Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets. Journal of Cancer Policy.
304. Haslam A, Gill J, Prasad V. The Frequency of Scans for Progression Free Survival. Cancer Reports. 2021.
303. Gill J, Sarpatwari A, Prasad V. The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clinic Proceedings. 2021
302. Lythgoe M, Prasad V. What does the approval of Aducanumab mean for Oncology Drug Products? European Journal of Cancer. 2021
301. Powel KL, Russler-Germain D, Prasad V*. Idacabtagene Vicleucel: Questions Regarding the Appropriate Use and Cost.
300. Gill J, Prasad V*. After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. 2021
299. Olivier T, Haslam A, Prasad V. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. 2021
298. Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V*. The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. 2021
297. Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V. Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature [published online ahead of print, 2021 Sep 7]. JAMA Intern Med. 2021;e214826. doi:10.1001/jamainternmed.2021.4826
296. Sharp J, Khaki A, Prasad V*. Use of Second-Line Immunotherapy in Control Arms of Randomized Controlled Trials in Kidney Cancer Seeking to Move Immunotherapy to the Front Line. 2021
Video explanation of the paper
295. Kim MS, Prasad V*. Nested and Adjacent Subgroups in Oncology Trials: When the incentives of companies and patients diverge. 2021
294. Jenei K, Meyers D, Prasad V. The inclusion of women in global oncology drug trials: A review of the past 20 years. 2021
293. Kim MS, Prasad V*. New drugs and options can enhance patient outcomes: But can they also erode them? European Journal of Cancer. 2021
292. Gill J, Sarpatwari A, Prasad V*. The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting.
291. Banerjee R, Prasad V*. Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review. JAMA Network Open. 2021
290. Prasad V*. Reliable, Cheap, Fast and Few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?. European Journal of Clinical Investigation. 2021
289. Powell K, Lythgoe M, Prasad V. The ODAC Votes of April 27-29: Implications for the Fate of Accelerated Approval. JAMA Oncology. 2021
288. Mohyuddin M, Ouchverdzie E, Goodman A, Prasad V. The Landscape of Trials for Smoldering Multiple Myeloma. Trial Design and Lessons Learnt. Leukemia and Lymphoma. 2021
287. Kim MS, Prasad V. When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence Based Medicine.
286. Smith CE, Prasad V. Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. JAMA Network Open. 2021
285. Mohyddin M, Abdullah A-O, McClune B, Goodman A, Prasad V. Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet. 2021
284. Kahl S, Prasad V, Palumbo A. The Regulatory Saga of Fedratinib. Journal of Oncology Pharmacy Practice. 2021
283. Mohyuddin M, Koehn K, Abdullah A-O, Goodman A, Prasad V. Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Network Open. 2021
282. Desai A, Prasad V. Low Dose CT for Lung Cancer: Time to Implement or Unresolved Questions? JGIM. 2021
281. Haslam A, Kim MS, Prasad V. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Annals of oncology 2021
280. Lythgoe M, Krell J, Savage P, Prasad V. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020. Prostate Cancer and Prostatic Diseases. 2021
279. Meyers D, Chisamore T, McInnes M, Gyawali B, Prasad V, Booth C. Industry payments to US physicians for cancer therapeutics; An analysis of the 2016-2018 open payments datasets. Journal of Cancer Policy. 2021
278. Powell K, Prasad V. Old-fashioned Intelligence Will Always Be Needed in Medicine. As Part of a Debate. European Urology Focus. 2021
277. DelPaggio J, Berry J, Hopman W, Eisenhauer E, Prasad V, Gyawali B, Booth C. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncology. 2021
276. Mohyuddin G, Koehn K, Sborov D, McClune B, Abdullah A, Goodman A, Prasad V. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematology. 2021
275. Kwon D, Booth C, Prasad V. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? European Urology. 2021
274. Prasad V, Kim MS. Approval and Coverage of Cancer Drugs in England, Canada, and the US. JAMA Internal Medicine. 2021
273. Kareff S, Samtani S, Burroto M, Prasad V, Kim C. Current landscape of immunotherapy trials involving the PD-(L)1 axis in intrathoracic tumors. Journal of Thoracic Oncology. 2021
272. Smith CS, Prasad V. Targeted cancer therapies. American Journal of Family Practice. 2021
2020
271. Gill J, Prasad V. Pembrolizumab for Non–Muscle-Invasive Bladder Cancer—A Costly Therapy in Search of Evidence. JAMA Oncology. 2020
270. Chen EY, … Prasad V… Kardosh A. Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. JOP. 2020
269. Hall W, ….Prasad V….Lawton C. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncology 2020.
268. DeMartino P, Miljovic M, Prasad V. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. Jama Internal Medicine. 2020
267. Goodman A, Kim MS, Prasad V. Persistent Challenges with Treating Multiple Myeloma Early. Blood. 2020
266. Tao D, Kartika T, Tran A, Prasad V. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response? EJC. 2020
265. Gill J, Prasad V. N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA. Trends In Cancer. 2020
264. Torgenson T, Wayant C,… Prasad V, Vassar M. Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence Based Med. 2020
263. Waters R, Prasad V. How Often Do Highly Promising Cancer Biology Discoveries Translate into Effective Treatments? Annals of Oncology. 2020
262. Banerjee R, Prasad V. Pragmatic trials with Prespecified Subgroups. Nature Reviews Clinical Oncology 2020.
261. Rosen K, Prasad V, Chen E. Censored patients in Kaplan–Meier plots of cancer drugs: An empirical analysis of data sharing. EJC. 2020
260. Desai A, Prasad V. Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap? JAMA oncology. 2020
259. Tran A, Prasad V. Drug Repurposing for Cancer Treatments: A Well Intentioned but Misguided Strategy. Lancet Oncology. 2020
258. Haslam A, Gill J, Prasad V. The Response Rate of Alternative Treatments for Drugs Approved On the Basis of Response Rate. International Journal of Cancer. 2020
257. Prasad V. Addeo A. The Approval of Pembrolizumab for TMB high, Was it a wise decision? No. Annals of Oncology. Annals of Oncology. 2020
256. Banerjee R, Prasad V. Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? JAMA Network Open. 2020
255. Tran A, Miljkovic M, Prasad V. Analysis of Estimated Clinical Benefit of Newly Approved Drugs for US Patients with Acute Myeloid Leukemia. Leukemia Research.2020
254. Kim MS, Prasad V. US Food and Drug Administration Approvals for Bruton Tyrosine Kinase Inhibitors in Patients With Chronic Lymphocytic Leukemia: Potential Inefficiencies in Trial Design and Evidence Generation. Cancer. 2020.
253. Gill J, Cetnar J, Prasad V. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. Trends in Cancer. 2020
252. Hilal T, Gonzales-Velez M, Prasad V. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. Jama Internal Medicine. 2020
251. Maldonado E, Parsons S, Chen E, Prasad V. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Oncology. 2020.
250. Tran A, Klossner W, Crain T, Prasad V. Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis. BMJ Open. 2020
249. Nishikawa G, Booth C, Prasad V. Olaparib for BRCA Mutant Pancreas Cancer: Should the POLO Trial Change Clinical Practice? Cancer. 2020
248. Perez D, Fox-Lee R, Bien J, Prasad V. Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). Mayo Clinic Proceedings. 2020
247. Chen E, Haslam A, Prasad V. FDA Acceptance of Surrogate Endpoints for Cancer Drug Approval: 1992-2019. Jama Intetrnal Medicine. 2020.
246. Hey SP, Gerlach CV , Dunlap C, Prasad V, Kesselheim AS. The Evidence Landscape in Precision Medicine. Science Translational Medicine. 2020.
245. Tran A, Prasad V. Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? PharmacoEconomics. 2020
244. Hazim A, Mills G, Prasad V, Haslam A, Chen EY. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials Journal of the National Comprehensive Cancer Network 18 (4), 428-433
243. Parsons S, Maldonado E, Prasad V. Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast and Non Small Cell Lung Cancer. JAMA Network Open. 2020.
242. Gill J, Haslam A, Crain T, Perez D, Prasad V. Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. JAMA Internal Medicine. 2020
241. Haslam, A, Prasad, V, Livingston, C. Medical reversals in low‐ and middle‐income countries. Int J Health Plann Mgmt. 2020; 35: 631– 638. https://doi.org/10.1002/hpm.2937
240. Haslam A, Gill J, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open. 2020;3(3):e200423.
239. Krigel A, Prasad V, Lebwohl B. News Coverage of the American Cancer Society’s Update to Colorectal Cancer Screening Guidelines. Mayo Clinic Proceedings. 2020;95(3):617-618.
238. Haslam A, Livingston C, Prasad V. Medical Reversals in Family Practice: A Review. Current Therapeutic Research. 2020;92:100579.
237. Haslam A, Herrera-Perez D, Gill J, Prasad V. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open. 2020;3(3):e200363.
236. Haslam, A., Gill, J., & Prasad, V. (2020). An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?, Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 18(2), 161-167.
235. Haslam A, Gill J, Prasad V. Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration’s Actions. Mayo Clinic Proceedings. 2020;95(2):424-426.
234. Prasad V. Our Best Weapons Against Cancer are Not Magic Bullets. Nature. 2020.
233. Gill J, Prasad V. When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor. Annals of Oncology. 2020.
2019
232. Gay ND, Tao D, Prasad V. Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. Curr Oncol. 2019;26(6):e791-e792.
231. Khaki AR, Gadi VK, Prasad V. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. Journal of the National Comprehensive Cancer Network : JNCCN. 2019;17(12):1456-1458.
230. Prasad V, Booth CM. Multiplicity in oncology randomised controlled trials: a threat to medical evidence? The Lancet Oncology. 2019;20(12):1638-1640.
229. Tao D, Prasad V. Concerning survival signal for eltrombopag in MDS/AML. Leukemia & Lymphoma. 2019:1-2.
228. de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Network Open. 2019;2(11):e1916091.
227. Ahn R, Herrera-Perez D, Prasad V. Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. JAMA internal medicine. 2019:e195145.
226. Haslam A, Prasad V, Livingston C. Medical reversals in low‐ and middle‐income countries. The International journal of health planning and management. 2019:10.1002/hpm.2937.
225. Kim MS, Prasad V. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.JAMA internal medicine.[Published online October 28, 2019]. 2019:1-3.
224. Beaulieu-Jones BK, Finlayson S, Yuan W, et al. Examining the Use of Real-World Evidence in the Regulatory Process. Clinical Pharmacology & Therapeutics. 2019:10.1002/cpt.1658.
223. Aspinall SL, Zhao X, Geraci MC… Prasad V. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer Medicine. 2019;8(15):6651-6661.
222. Luo J, Nishikawa G, Prasad V. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. Journal of cancer research and clinical oncology. 2019;145(9):2303-2311.
221. Gill J, Prasad V. A reality check of the accelerated approval of immune-checkpoint inhibitors. Nature reviews Clinical oncology. 2019;16(11):656-658.
220. Herrera-Perez, D., A. Haslam, T. Crain, J. Gill, C. Livingston, V. Kaestner, M. Hayes, D. Morgan, A. S. Cifu and V. Prasad. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. 2019. eLife 8: e45183.
219. Chapa J, Haslam A, Prasad V. Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? Mayo Clinic Proceedings. 2019;94(6):951-956.
218. Haslam A, Prasad V. Confirmatory Trials for Drugs Approved on a Single Trial. Circulation: Cardiovascular Quality and Outcomes. 2019;12(6):e005494
217. Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med. 2019;179(7):915–921.
216. Kim MS, Prasad V. Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. JAMA Network Open. 2019;2(5):e193981-e193981.
215. Nabhan C, Klink A, Prasad V. Real-world Evidence—What Does It Really Mean? JAMA Oncol. Published online May 16, 20195(6):781–783. doi:10.1001/
214. Greene P, Prasad V, Cifu A. Should Evidence Come with an Expiration Date? Journal of general internal medicine. 2019;34(7):1356-1357.
213. Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs Eligibility for and Response to Checkpoint Inhibitor Immunotherapy Drugs for Cancer. JAMA Network Open. 2019;2(5):e192535-e192535.
212. Hilal T, Sonbol MB, Prasad V. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA oncology. 2019;5(6):887-892.
211. Cifu AS, Vandross AL, Prasad V. Case Reports in the Age of Twitter. The American Journal of Medicine.2019;132(10):e725-e726.
210. Prasad V.K. Improving the design of pivotal clinical trials. Clinical advances in hematology & oncology : H&O 2019;17(3):150-52.
209. Gill J, Prasad V. Testing healthcare workers for latent tuberculosis: Is it evidence based, bio-plausible, both or neither? The American Journal of Medicine. 2019.
208. Chen EY, Joshi SK, Tran A, Prasad V. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Intern Med. Published online April 01, 2019.
207. Gill, J. and V. Prasad, Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. Canadian Medical Association Journal, 201;191(10): p. E272.
206. Mandrola J, Cifu A, Prasad V, Foy A. The Case for Being a Medical Conservative. The American journal of medicine. 2019;132(8):900-901.
205. Mandrola J, Cifu A, Prasad V, Foy A. The Reply. The American Journal of Medicine. 2019;132(9):e719.
204. Kim, M.S., G. Nishikawa, and V. Prasad, Cancer screening: A modest proposal for prevention. Cleveland Clinic journal of medicine. 2019;86(3):157-160.
203. Cook RJ, Gill J, Prasad V. Registration studies - when should patients be deemed ineligible for aggressive therapy? Nature reviews Clinical oncology 2019;16(6):333-34.
202. Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V. Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. The American journal of medicine. 2019;132(6):718-721.
201. Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. European Journal of Cancer. 2019;106:196-211.
200. Tao D, Schott S, Prasad V. The tradeoff of cancer drug regulatory policy: Faster approvals for one means less knowledge for another. Am J Med. 2019;132(3):e509-e511.
199. Prasad V.,Cifu A. The Necessity of Sham Controls. The American Journal of Medicine.2019;132(2):e29-e30.
198. Maldonado E, Parsons S, Chen EY-s, Haslam A, Prasad V. Estimation of U.S. patients with cancer who may respond to cytotoxic chemotherapy. Journal of Clinical Oncology. 2019;37(15_suppl):e18228-e18228.
197. Hazim AZ, Chen EY-s, Mills GB, Prasad V. The relationship between response and dose in published, contemporary phase 1 oncology trials. Journal of Clinical Oncology. 2019;37(15_suppl):e14583-e14583.
196. Gill J, Prasad V. A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. Research and Practice in Thrombosis and Haemostasis. 2019
195. B Gyawali, V Prasad; Making Adjuvant Therapy Decisions with Uncertain Data. Ann Oncol. 2019;30(3):361-364.
194. Hayes MJ, Prasad V. Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. Journal of Cancer Policy. 2019:100189.
2018
193. Parikh RB, Prasad V. Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs? Journal of Clinical Oncology 2018;37(4):266-68.
192. Parikh RB, Prasad V. Reply to C.J. Sweeney et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37(19):1680-1681.
191. Yoo SK, Ahmed AA, Hwang L, et al. Who is Tweeting in Oncology? Social Media (SM) Activity among Academic Leadership in 2018. International Journal of Radiation Oncology • Biology • Physics. 2018;102(3):e430.
190. Shanbhag S, Prasad V. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers? European Journal of Cancer.
189. Ahmed, Awad A., Stella K. Yoo, Shahil Mehta, Emma B. Holliday, Curtiland Deville, Neha Vapiwala, Lynn D. Wilson, Reshma Jagsi, Vinay Prasad, and Charles R. Thomas. 2018. 'Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies', Journal of Oncology Practice: JOP.18.00121.
188. Nishikawa G, Prasad V. Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ. 2018;362.
187. Hilal T, Prasad V. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission. Nature Reviews Clinical Oncology 2018 doi: 10.1038/s41571-018-0087-y
186. Tao D, Prasad V. Choice of control group in randomised trials of cancer medicine: are we testing trivialities? The Lancet Oncology 2018;19(9):1150-52. doi: 10.1016/S1470-2045(18)30501-1
185. Gill J, Prasad V. Improving observational studies in the era of big data. The Lancet. 2018;392(10149):716-717.
184. Hazim A, Prasad V. A pooled analysis of published, basket trials in cancer medicine. European Journal of Cancer. 2018;101:244-250.
183. Nishikawa G, Luo J, Prasad V. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer. 2018;101:143-151.
182. Prasad V., Lindner S. Why is Research in Early-Stage Cancer Research so Low? Journal of Cancer Policy. 2018.
181. Haslam A, Prasad V. Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose How Do We Know That? Circulation: Cardiovascular Quality and Outcomes. 2018; 11e004886.
180. Gill J, Obley AJ, Prasad V. Direct-to-Consumer Genetic Testing The Implications of the US FDA’s First Marketing Authorization for BRCA Mutation Testing. JAMA. 2018;319(23):2377–2378.
179. Nastoupil LJ, Prasad V, Flowers CR. The need to assess financial adverse events. The Lancet Haematology.
178. Deloughery EP, Prasad V. If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. Journal of General Internal Medicine. 2018.
177. Chen EY-s, Joshi SK, Prasad V. FDA acceptance of surrogate endpoints in later lines of therapy. Journal of Clinical Oncology 2018;36:6517.
176. Tao DL, Gay ND, Prasad V. Statistical significance of bevacizumab trials when considering the portfolio of all studies. Journal of Clinical Oncology 2018;36:6551.
175. Gyawali B, Prasad V. Pemetrexed in Nonsquamous Non–Small-Cell Lung Cancer The Billion Dollar Subgroup Analysis. JAMA Oncol. 2018;4(1):17–18
174. Prasad V. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15(1):11-12.
173. Lu E, Shatzel J, Shin F, Prasad V. What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature. Semin Oncol. 2017;44.
172. Prasad V, McCabe C, Mailankody S. Low drug approval standards. NRCO
171. Marquart J, Chen EY, Prasad V. Estimation of the percentage of us patients with cancer who benefit from genome-driven oncology. JAMA Oncology. 2018.
170. Shatzel, J. J., M. M. Daughety, V. Prasad, and T. G. DeLoughery. 2018. 'PFO closure for secondary stroke prevention: is the discussion closed?', J Thromb Thrombolysis, 46: 74-76.
169. Prasad V, Kaestner V, Mailankody S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncol. 2018;4(2):157-158.
168. Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? Annals of Oncology. 2018:mdy116-mdy116.
167. Gerrity MS, Prasad V, Obley AJ. Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. JAMA Intern Med. 2018;178(6):743–744. doi:10.1001/jamainternmed.2018.0869
166. Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor t-cell immunotherapy. JAMA Oncology. 2018.
165. DeLoughery EP, Prasad V. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation. Ann Oncol. 2018;29(3):527-529.
164. Kaestner V, Edmiston JB, Prasad V. The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. CMAJ open. 2018;6(1):E57-e62.
163. Prasad V. Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it. Annals of Oncology. 2018;29(2):298-300.
162. Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG. Reversal of warfarin era thinking. Journal of internal medicine. 2018;283(4):408-410.
161. Chen EY, Prasad V. Crossover is not associated with faster trial accrual. Ann Oncol. 2018;29(3):776-777.
160. Hayes MJ, Kaestner V, Mailankody S, Prasad V. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ open. 2018;6(1):E31-e38.
159. Prasad V. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? JAMA pediatrics. 2018;172(2):123-125.
158. Ahn, Rosa, and Vinay Prasad. 2018. 'Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?', Cardiovascular Drugs and Therapy.
157. Wagner J, Marquart J, Ruby J, et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ. 2018;360.
156. Rebuttal to paper by Kurzrock et. al. Vinay Prasad 2019.
155. Luo J, Prasad V. The US Food and Drug Administration’s use of pathologic complete response as regulatory endpoint: Did it pay off? Journal of Cancer Policy. 2018;16:49-51.
154. Prasad V. Cost-effectiveness of nusinersen for spinal muscular atrophy—reply. JAMA pediatrics. 2018.
153. Michael J. Hayes and Vinay Prasad, “Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings,” Hastings Center Report 48, no. 2 (2018): 10–13. 10.1002/hast.833
2017
152. Prasad V. Do cancer drugs improve survival or quality of life? BMJ. 2017;359.
151. Prasad V, Kaestner V, Mailankody S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncol. 2018;4(2):157-158.
150. Tayapongsak Duggan K, De Jesus K, Kemp R, Prasad V. Use of word “unprecedented” in the media coverage of cancer drugs: Do “unprecedented” drugs live up to the hype? Journal of Cancer Policy. 2017;14:16-20.
149. Prasad V. Unanticipated outcomes: A medical memoir—a book review. JAMA Internal Medicine. 2018;178(1):11-12.
148. Prasad V. Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy? J Gen Intern Med. 2018;33(1):3-5.
147. Tao DL, Boothby A, McLouth J, Prasad V. Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. JAMA Intern Med. 2017;177(3):425–427.
146. Kaestner V, Prasad V. The availability of jobs in the biopharmaceutical industry is 45-fold greater for hematology oncology than medical specialties. Blood Cancer Journal. 2017;7:e619.
145. Kaestner V, Prasad V. Financial conflicts of interest among editorialists in high-impact journals. Blood Cancer Journal. 2017;7:e611.
144. Prasad V, Kaestner V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Seminars in Oncology. 2017.
143. Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Medicine. 2017;15(1):134.
142. Dreicer JJ, Mailankody S, Fahkrejahani F, Prasad V. Clinically meaningful benefit: real world use compared against the American and European guidelines. Blood Cancer Journal. 2017;7(12):645.
141. Mailankody S, Prasad V. Pharmaceutical Marketing for Rare Diseases Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. JAMA. 2017;317(24):2479–2480.
140. Goldstein, D. A., Bilal, U. and Prasad, V. (2017), Pembrolizumab as first‐line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?. Cancer, 123: 3872-3874.
139. Lammers A, Edmiston J, Kaestner V, Prasad V. Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings. Mayo Clin Proc. 2017;92(7):1164-1166.
138. Prasad V, De Jesus K, Mailankody S. A further strategy to combat the high price of anticancer drugs. Nat Rev Clin Oncol. 2017.
137. Gyawali B, Prasad V. Combining drugs and extending treatment - a PFS end point is not sufficient. Nat Rev Clin Oncol. 2017;14(9):521-522.
136. Kaestner V, Brown A, Tao D, Prasad V. Conflicts of interest in Twitter. The Lancet Haematology. 2017;4(9):e408-e409.
135. Prasad V. How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. The American Journal of Medicine. 2017;130(7):769-770.
134. Gyawali B, Prasad V. Drugs that lack single-agent activity: are they worth pursuing in combination? Nat Rev Clin Oncol. 2017;14(4):193-194.
133. De Jesus-Morales K, Prasad V. Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote. Hastings Center Report. 2017;47(3):9-14.
132. Prasad V, Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med. 2017.
131. Gyawali B, Prasad V. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. Nat Rev Clin Oncol. 2017.
130. Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381-390.
129. Lammers A, Wang R, Cetnar J, Prasad V. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. Blood cancer journal. 2017;7(12):637-637.
2016
128. Prasad V, Oseran A. Multiple Comparisons in Variation of Care Research. University of Ottawa Journal of Medicine. 2017;7(1).
127. Mailankody S, Prasad V. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. JAMA Oncol. 2017;3(7):889-890.
126. Lammers A, DeLoughery T, Prasad V. Heparin-induced thrombocytopenia: a tremendous opportunity for randomization. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2017;28(3):272-274.
125. Vandross A, Prasad V, Mailankody S. ASCO Plenary Sessions: impact, legacy, future. Semin Oncol. 2016;43(3):321-326.
124. Vaduganathan M, Prasad V. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? European Journal of Heart Failure. 2016;18(2):128-132.
123. Prasad V, Wang R, Afifi S, Mailankody S. The rising price of cancer drugs—a new old problem? JAMA Oncology. 2017;3(2):277-278.
122. Prasad V, Oseran A, Fakhrejahani F. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival? European Journal of Cancer. 2016;54:159-162.
121. Prasad V, Mailankody S. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Mayo Clin Proc. 2016;91(6):707-712.
120. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives”—and what we can do about it. BMJ. 2016;352.
119. Prasad V, Kumar H, Mailankody S. Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. Journal of Global Oncology. 2016;2(1):1-3.
118. Abola MV, Prasad V. Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clin Proc. 2016;91(11):1668-1670.
117. Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leukemia research. 2016;48:73-77.
116. Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81-e86.
115. Prasad V. Precision medicine in diffuse large B-cell lymphoma: Hype or hope? Eur J Cancer. 2016;68:22-26.
114. Prasad V. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? Medical hypotheses. 2016;93:71-73.
113. Prasad V. How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(3):365-366.
112. Prasad V, Rajkumar SV. Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward. Blood Cancer Journal. 2016;6(11):e489.
111. Prasad V. Translation failure and medical reversal: Two sides to the same coin. Eur J Cancer. 2016;52:197-200.
110. Parikh RB, Prasad V. Blood-based screening for colon cancer: A disruptive innovation or simply a disruption? JAMA. 2016;315(23):2519-2520.
109. Massey PR, Wang R, Prasad V, Bates SE, Fojo T. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist. 2016;21(3):261-268.
108. Prasad V. Perspective: The precision-oncology illusion. Nature. 2016;537:S63.
107. Mailankody S, Prasad V. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. Jama. 2016;316(3):271-272.
106. Mailankody S, Prasad V. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist. 2016;21(9):1031-1032.
105. Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clinic Proceedings. 2016;91(6):713-725.
104. Gyawali B, Prasad V. Same Data; Different Interpretations. Journal of Clinical Oncology. 2016;34(31):3729-3732.
103. Dhruva SS, Prasad V. Application of medicare’s new technology add-on payment program for blinatumomab. JAMA Oncology. 2016;2(2):165-166.
102. Cifu A, Prasad V. Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off? J Gen Intern Med. 2016;31(11):1367-1368.
101. Boothby A, Wang R, Cetnar J, Prasad V. Effect of the American Society of Clinical Oncology’s conflict of interest policy on information overload. JAMA Oncology. 2016;2(12):1653-1654.
100. Bien J, Prasad V. Future jobs of FDA’s haematology-oncology reviewers. BMJ. 2016;354.
99. Beer TM, Prasad V. Taking care of our friends and neighbors: DeVita’s the death of cancer and the challenge of letting go. JAMA Oncology. 2017;3(1):16-17.
98. Abola MV, Prasad V. Characteristics and conflicts of public speakers at meetings of the oncologic drugs advisory committee to the us food and drug administration. JAMA Internal Medicine. 2016;176(3):389-391.
97. Abola MV, Prasad V. The use of superlatives in cancer research. JAMA Oncology. 2016;2(1):139-141.
2015
96. Tilak G, Prasad V, Jena AB. Authorship Inflation in Medical Publications. Inquiry : a journal of medical care organization, provision and financing. 2015;52.
95. Thomas A, Chen Y, Yu T, Gill A, Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;6(18):16766-16773.
94. Prasad V, Vandross A. Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc. 2015;90(12):1639-1649.
93. Prasad V, Oseran A. Do we need randomised trials for rare cancers? Eur J Cancer. 2015;51(11):1355-1357.
92. Prasad V, Mailankody S. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015;126(15):1860-1861.
91. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175.
90. Prasad V, Goldstein JA. Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. Eur J Cancer. 2015;51(17):2718-2723.
89. Prasad V, Diener-West M. Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2015;187(9):E276-278.
88. Prasad V, Bilal U. The role of censoring on progression free survival: oncologist discretion advised. Eur J Cancer. 2015;51.
87. Prasad V, Berger VW. Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc. 2015;90(9):1171-1175.
86. Prasad V. But how many people died? Health outcomes in perspective. Cleveland Clinic journal of medicine. 2015;82(3):146-150.
85. Prasad V. Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents. American family physician. 2015;92(8):678-680.
84. Prasad V. Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing? Eur J Cancer. 2015;51(16):2272-2274.
83. Prasad V. Use of the Word “Cure” in the Oncology Literature. American Journal of Hospice and Palliative Medicine®. 2014;32(5):477-483.
82. Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology & Therapy. 2015;16(7):1014-1018.
81. Mailankody S, Prasad V. Susan Bates, M.D., and Antonio “Tito” Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. The Oncologist. 2015;20(11):1344-1346.
80. Mailankody S, Prasad V. Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncology. 2015;1(4):539-540.
79. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175.
78. Jena AB, Prasad V, Goldman DP, Romley J. Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Intern Med. 2015;175(2):237-244.
77. Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol. 2015;1(6):787-795.
76. Huded C, Prasad V. Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2015;15(6):379-386.
75. Goldstein JA, Prasad V. Disease Specific Productivity of American Cancer Hospitals. PLOS ONE. 2015;10(3):e0121233.
74. Cifu AS, Prasad VK. Medical Debates and Medical Reversal. Journal of General Internal Medicine. 2015;30(12):1729-1730.
73. Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. Lancet Oncol. 2015;16(4):364-366.
72. Burotto M, Prasad V. Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. Cancer. 2015;121(16):2668-2670.
71. Rho J, Ho N, Prasad V. Roflumilast in COPD: Response. CHEST. 2015;148(1):e31-e32.
2014
70. Vaduganathan M, Prasad V. Modern drug development: which patients should come first? JAMA. 2014;312.
69. Selvaraj S, Borkar DS, Prasad V. Media coverage of medical journals: do the best articles make the news? PLoS One. 2014;9(1):e85355.
68. Rho J, Ho N, Prasad V. Counterpoint: Were Industry-Sponsored Roflumilast Trials Appropriate? No. Chest. 2014;145(5):939-942.
67. Prasad V, Vandross A. Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? Journal of cancer research and clinical oncology. 2014;140(4):521-524.
66. Prasad V, Rho J, Selvaraj S, Cheung M, Vandross A, Ho N. Can a resident's publication record predict fellowship publications? PLoS One. 2014;9(3):e90140.
65. Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620-1629.
64. Prasad V, Mailankody S. The accelerated approval of oncologic drugs: Lessons from ponatinib. JAMA. 2014;311(4):353-354.
63. Prasad V, Jena AB. The Peltzman effect and compensatory markers in medicine. Healthcare (Amsterdam, Netherlands). 2014;2(3):170-172.
62. Prasad V, Ioannidis JP. Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. Implementation Science. 2014;9(1):1.
61. Prasad V, Ho N. Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? Journal of clinical epidemiology. 2014;67(4):361-363.
60. Prasad V, Grady C. The Misguided Ethics of Crossover Trials. Contemporary clinical trials. 2014;37(2):167-169.
59. Prasad V, Goldstein JA. US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity? PLOS ONE. 2014;9(9):e107803.
58. Prasad V, Cifu A. Eliminating chronic kidney disease... as a diagnosis. Polskie Archiwum Medycyny Wewnetrznej. 2014;124(1-2):7-9.
57. Prasad V. Shameful. CMAJ : Canadian Medical Association Journal. 2014;186(6):472-472.
56. Prasad V. Rosiglitazone, medical reversal, and back to basics for diabetes. American family physician. 2014;90(6):368, 370.
55. Prasad V. STatins, primary prevention, and overall mortality. Annals of Internal Medicine. 2014;160(12):867-869.
54. Prasad V. The withdrawal of drugs for commercial reasons: The incomplete story of tositumomab. JAMA Internal Medicine. 2014;174(12):1887-1888.
53. Prasad V. It is time to stop screening for prostate cancer. JAMA Internal Medicine. 2014;174(11):1841-1842.
52. Prasad V. Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't? Journal of cancer research and clinical oncology. 2014;140(8):1353-1357.
51. Mailankody S, Prasad V. Comparative Effectiveness Questions in Oncology. New England Journal of Medicine. 2014;370(16):1478-1481.
50. Jena AB, Sun EC, Prasad V. Does the Declining Lethality of Gunshot Injuries Mask a Rising Epidemic of Gun Violence in the United States? Journal of General Internal Medicine. 2014;29(7):1065-1069.
49. Jena AB, Prasad V, Romley JA. Long-term Effects of the 2003 ACGME Resident Duty Hour Reform on Hospital Mortality. Mayo Clinic proceedings. 2014;89(7):1023-1025.
48. Jena AB, Prasad V. Primary care physicians' role in counseling about gun safety. American family physician. 2014;90(9):619-620.
47. Jena AB, DePasse JW, Prasad V. The Declining Demand for Hospital Care as a Rationale for Duty Hour Reform. Journal of General Internal Medicine. 2014;29(10):1400-1403.
46. Abola MV, Prasad V, Jena AB: Association between treatment toxicity and outcomes in oncology clinical trials. Ann Oncol 25:2284-9, 2014
2013
45. Shea N, Prasad V. Open Issues with Open Access Publication. The American Journal of Medicine. 2013;126(7):563-564.
44. Selvaraj S, Prasad V. Characteristics of cluster randomized trials: Are they living up to the randomized trial? JAMA Internal Medicine. 2013;173(4):313-315.
43. Prasad V, Vandross A, Toomey C, et al. A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings. 2013;88(8):790-798.
42. Prasad V, Rho J, Cifu A. The inferior vena cava filter: How could a medical device be so well accepted without any evidence of efficacy? JAMA Internal Medicine. 2013;173(7):493-495.
41. Prasad V, Jorgenson J, Ioannidis JP, Cifu A. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. Journal of clinical epidemiology. 2013;66(4):361-366.e364.
40. Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? Jama. 2013;309(3):241-242.
39. Prasad V, Ho N. In vitro versus in vivo culture sensitivities: an unchecked assumption? Southwest Journal of Pulmonary Critical Care. 2013;6(3):125-7.
38. Prasad V, Cifu A. The reversal of cardiology practices: interventions that were tried in vain. Cardiovascular Diagnosis and Therapy. 2013;3(4):228-235.
37. Prasad V. Why resident physicians stay late. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2013;185(13):1184.
36. Prasad V. Persistent reservations against the premedical and medical curriculum. Perspectives on Medical Education. 2013;2(5-6):335-339.
35. Prasad V. Taking care of sick patients. CMAJ : Canadian Medical Association Journal. 2013;185(11):1008-1008.
34. Prasad V. Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews. Mayo Clinic Proceedings. 2013;88(10):1046-1050.
33. Prasad V. The overdiagnosis of pneumonia. Cleveland Clinic journal of medicine. 2013;80(10):616-618.
32. Prasad V. Double-crossed: why crossover in clinical trials may be distorting medical science. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(5):625-627.
31. Kim JK, Rho J, Prasad V. Handheld ultrasounds: pocket sized, but pocket ready? Am J Med. 2013;126(10):845-846.
30. Kim J, Rho J, Prasad V: Evidence based practice in chronic musculoskeletal pain? Alternative and Complementary Therapies 19:49-58, 2013
29. Jena AB, Prasad V. Duty hour reform in a shifting medical landscape. J Gen Intern Med. 2013;28(9):1238-1240.
28. Ioannidis JP, Prasad V. Evaluating health system processes with randomized controlled trials. JAMA Intern Med. 2013;173(14):1279-1280.
27. Huded C, Rosno J, Prasad V. When research evidence is misleading. The virtual mentor : VM. 2013;15(1):29-33.
26. Ho N, Kim J, Prasad V. Dense breasts and legislating medicine. Cleveland Clinic journal of medicine. 2013;80(12):768-770.
25. Prasad V, Cifu A. A medical burden of proof: Towards a new ethic. BioSocieties. 2012;7(1):72-87.
2012
24. Prasad V, Vandross A. Cardiovascular primary prevention: how high should we set the bar? Arch Intern Med. 2012;172(8):656-659; discussion 659.
23. Prasad V, Rho J, Selvaraj S, Toomey C, Vandross A, Ho N. Publication Trends Among Internal Medicine Residents and Graduates. The American Journal of Medicine. 2012;125(9):939-944.
22. Prasad V, Rho J, Cifu A. The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. Arch Intern Med. 2012;172(12):955-958.
21. Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012;33(3):199-208.
20. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. Jama. 2012;307(1):37-38.
19. Prasad V, Cheung M, Cifu A. Chest pain in the emergency department: The case against our current practice of routine noninvasive testing. Archives of Internal Medicine. 2012;172(19):1506-1509.
18. Prasad V. An unmeasured harm of screening. Archives of Internal Medicine. 2012;172(19):1442-1443.
17. Prasad V. Holiday reading: The facts are the facts. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012;184(18):2029-2030.
16. Prasad V. The conundrum of cost-effectiveness. Cleveland Clinic journal of medicine. 2012;79(9):610-611.
15. Prasad V. The apples and oranges of cost-effectiveness. Cleveland Clinic journal of medicine. 2012;79(6):377-379.
2011
14. Straus D, Prasad V, Munoz L. Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. Arquivos de neuro-psiquiatria. 2011;69(6):981-987.
13. Prasad V, Thistlethwaite W, Dale W. Effect of clinical vignettes on senior medical students' opinions of climate change. Southern medical journal. 2011;104(6):401-404.
12. Prasad V, Gall V, Cifu A. The frequency of medical reversal. Archives of Internal Medicine. 2011;171(18):1675-1676.
11. Prasad V, Cifu A. Medical Reversal: Why We Must Raise the Bar Before Adopting New Technologies. The Yale Journal of Biology and Medicine. 2011;84(4):471-478.
10. Prasad V, Bonow RO. The cardiovascular biomarker conundrum: challenges and solutions. Jama. 2011;306(19):2151-2152.
9. Prasad V. Perspective: Why There Must Be a Meditative Medicine. Alternative and Complementary Therapies. 2011;17(5):274-278.
8. Prasad V. Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. Teach Learn Med. 2011;23(4):337-341.
7. Ho N, Prasad V. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. Journal of clinical gastroenterology. 2011;45(4):379-380.
2010
6. Prasad V. Holiday reading: A la carte medicine. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2010;182(18):2011-2012.
5. Prasad V. Reclaiming the morbidity and mortality conference: between Codman and Kundera. Medical humanities. 2010;36(2):108-111.
4. Prasad V: Language in the end. Explaining the death of a loved one. J Gen Intern Med 25:884-5, 2010
3. Prasad V. Perspective: beyond storytelling in medicine: an encounter-based curriculum. Academic medicine : journal of the Association of American Medical Colleges. 2010;85(5):794-798.
2. Prasad V. Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. Medical hypotheses. 2010;75(6):639-641.
2009
1. Prasad, V. (2009). Toward a Meaningful Alternative Medicine. The Hastings Center Report, 39(5), 16-18.